Clinical Trials Logo

Retinal Disease clinical trials

View clinical trials related to Retinal Disease.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03846193 Active, not recruiting - Clinical trials for Macular Degeneration

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Start date: December 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to AMD

NCT ID: NCT03422965 Active, not recruiting - Diabetes Mellitus Clinical Trials

Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus

Start date: May 8, 2017
Phase: N/A
Study type: Interventional

This study is directed to evaluate the role of Optical Coherence Tomography Angiography (OCT-A) in the evaluation of the perifoveal vascular network in type 1 diabetic patients, and to investigate the relationship between OCT-A-derived parameters and demographic and clinical factors, as metabolic control and duration of the disease.

NCT ID: NCT01217762 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical feasibility of the IRay System for the treatment of wet age-related macular degeneration (AMD).

NCT ID: NCT00481546 Active, not recruiting - Retinal Diseases Clinical Trials

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

LCA
Start date: July 2007
Phase: Phase 1
Study type: Interventional

A recombinant adeno-associated virus serotype 2 (rAAV2) vector has been altered to carry the human RPE65 (hRPE65) gene. This vector has been shown to restore vision in animal models that resemble human RPE65-associated Leber congenital amaurosis (LCA), an incurable retinal degeneration that causes severe vision loss. The proposed study is an open label, Phase I clinical trial of subretinal rAAV2-CBSB-hRPE65 administration to individuals with RPE65-associated retinal disease. Five cohorts will be included in this trial. Cohorts 1, 2 and 4 will consist of individuals 18 years of age and older. Cohorts 3 and 5 will consist of individuals between the ages of 8 and 17, inclusive. Enrollment in Cohorts 3 and 5 will begin only after confirming the safety of rAAV2-CBSB-hRPE65 administration in the older groups of participants. This trial will lead to a greater understanding of the safety and thereby potential value of gene transfer in RPE65-associated retinal disease and will have implications for other forms of retinal degenerative disease amenable to this type of intervention. The goal of this clinical trial is to determine the safety of uniocular subretinal administration of rAAV2-CBSB-hRPE65 in individuals with RPE65-associated retinal disease. Ocular and systemic toxicity will be assessed prior to and following vector administration to determine if there are adverse changes that may be associated with vector administration.